{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26","upperLimit":"59","value":"43"}]}],"title":"Matched Related Donors (MRD) n=38"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"34","value":"22"}]}],"title":"Matched Unrelated Donors (MUD) n=53"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"30","value":"15"}]}],"title":"Haploidentical related (HAPLO) donor n=33"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"description":"Progression-free survival (PFS) rates after stem cell transplant were estimated using the Kaplan-Meier method. We performed univariate comparisons by using the log-rank test. PFS was defined as the period of time between the day of transplantation and either the day underlying disease progression was documented or death occurred by any cause. The following variables were considered as confounders: recipient age, recipient sex, disease (myeloid or lymphoid), disease risk (standard or high), and donor type (MRD, MUD, or HAPLO donor). The percentage of participants progression free at 2 years is reported by donor type. Progression = \\> 25% increase of serum M-protein and/or urine M-protein. Also, an absolute increase in bone marrow plasma cells \\> 10%, new bone lesions or soft tissue plasmacytomas or increase in the size of existing bone lesions or soft tissue plasmacytomas or development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-myeloablative Stem Cell Transplant (SCT): Donor will receive Granulocyte colony-stimulating factor (G-CSF) 8 mcg/kg/d subcutaneously twice daily for 4 days, until pheresis is completed or until white blood cells \\> 100,000. Recipients will be premedicated with Benadryl 50 mg intravenously (IV) or orally (PO), and acetaminophen 650 mg PO (or hydrocortisone 50-100 mg IV on first day). The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. For the myeloid group, the prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The Peripheral Blood Stem Cells (PBSCs) will be infused over 2-4 days. Participant evaluations will occur 2 times per week by physical exam for toxicity through day 45.","id":"OG000","title":"Cohort A & B - Lymphoid & Myeloid Disease"}],"paramType":"NUMBER","populationDescription":"All participants who received transplant. Cohort A (n=62) had acute or chronic leukemia (ALL or CLL), lymphoma, or myeloma. Cohort B (n=62) had acute or chronic myeloid leukemia (AML or CML), myelodysplastic disorder or myeloproliferative disorder. Analysis by type of donor (Matched Unrelated Donor; Matched Related Donor; Haplo-identical).","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}